Literature DB >> 20117457

Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.

Christopher R deFilippi1, Robert H Christenson, John S Gottdiener, Willem J Kop, Stephen L Seliger.   

Abstract

OBJECTIVES: This study sought to determine whether serial measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in community-dwelling elderly people would provide additional prognostic information to that from traditional risk factors.
BACKGROUND: Accurate cardiovascular risk stratification is challenging in elderly people.
METHODS: NT-proBNP was measured at baseline and 2 to 3 years later in 2,975 community-dwelling older adults free of heart failure in the longitudinal CHS (Cardiovascular Health Study). This investigation examined the risk of new-onset heart failure (HF) and death from cardiovascular causes associated with baseline NT-proBNP and changes in NT-proBNP levels, adjusting for potential confounders.
RESULTS: NT-proBNP levels in the highest quintile (>267.7 pg/ml) were independently associated with greater risks of HF (hazard ratio [HR]: 3.05; 95% confidence interval [CI]: 2.46 to 3.78) and cardiovascular death (HR: 3.02; 95% CI: 2.36 to 3.86) compared with the lowest quintile (<47.5 pg/ml). The inflection point for elevated risk occurred at NT-proBNP 190 pg/ml. Among participants with initially low NT-proBNP (<190 pg/ml), those who developed a >25% increase on follow-up to >190 pg/ml (21%) were at greater adjusted risk of HF (HR: 2.13; 95% CI: 1.68 to 2.71) and cardiovascular death (HR: 1.91; 95% CI: 1.43 to 2.53) compared with those with sustained low levels. Among participants with initially high NT-proBNP, those who developed a >25% increase (40%) were at higher risk of HF (HR: 2.06; 95% CI: 1.56 to 2.72) and cardiovascular death (HR: 1.88; 95% CI: 1.37 to 2.57), whereas those who developed a >25% decrease to <or=190 pg/ml (15%) were at lower risk of HF (HR: 0.58; 95% CI: 0.36 to 0.93) and cardiovascular death (HR: 0.57; 95% CI: 0.32 to 1.01) compared with those with unchanged high values.
CONCLUSIONS: NT-proBNP levels independently predict heart failure and cardiovascular death in older adults. NT-proBNP levels frequently change over time, and these fluctuations reflect dynamic changes in cardiovascular risk. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117457      PMCID: PMC2840257          DOI: 10.1016/j.jacc.2009.07.069

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


  32 in total

1.  Time-dependent ROC curves for censored survival data and a diagnostic marker.

Authors:  P J Heagerty; T Lumley; M S Pepe
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

3.  Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.

Authors:  Morten Schou; Finn Gustafsson; Andreas Kjaer; Per R Hildebrandt
Journal:  Eur Heart J       Date:  2007-01-11       Impact factor: 29.983

4.  Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group.

Authors:  C D Furberg; T A Manolio; B M Psaty; D E Bild; N O Borhani; A Newman; B Tabatznik; P M Rautaharju
Journal:  Am J Cardiol       Date:  1992-05-15       Impact factor: 2.778

5.  Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

Authors:  Inder S Anand; Lloyd D Fisher; Yann-Tong Chiang; Roberto Latini; Serge Masson; Aldo P Maggioni; Robert D Glazer; Gianni Tognoni; Jay N Cohn
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

6.  N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Authors:  Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Per R Hildebrandt
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

7.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

8.  Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group.

Authors:  P M Rautaharju; T A Manolio; D Siscovick; S H Zhou; J M Gardin; R Kronmal; C D Furberg; N O Borhani; A Newman
Journal:  Hypertension       Date:  1996-07       Impact factor: 10.190

9.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.

Authors:  David A Morrow; James A de Lemos; Michael A Blazing; Marc S Sabatine; Sabina A Murphy; Petr Jarolim; Harvey D White; Keith A A Fox; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2005-12-14       Impact factor: 56.272

10.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.

Authors:  Paul M McKie; Richard J Rodeheffer; Alessandro Cataliotti; Fernando L Martin; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Margaret M Redfield; John C Burnett
Journal:  Hypertension       Date:  2006-04-03       Impact factor: 10.190

View more
  57 in total

1.  Left ventricular ejection fraction assessment in older adults: an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death?

Authors:  Christopher R deFilippi; Robert H Christenson; Willem J Kop; John S Gottdiener; Min Zhan; Stephen L Seliger
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

2.  Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.

Authors:  Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

3.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.

Authors:  Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger
Journal:  JAMA       Date:  2010-11-15       Impact factor: 56.272

Review 4.  Prevention of heart failure in the elderly: when, where and how to begin?

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 5.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

6.  N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Nona Sotoodehnia; Christopher DeFilippi; David S Siscovick; John S Gottdiener; Richard A Kronmal
Journal:  Heart Rhythm       Date:  2010-10-30       Impact factor: 6.343

7.  Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Pamela L Lutsey; Vijay Nambi; Christopher R deFilippi; Susan R Heckbert; Mary Cushman; Christie M Ballantyne
Journal:  Vasc Med       Date:  2014-02       Impact factor: 3.239

8.  Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.

Authors:  Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer
Journal:  Metabolism       Date:  2016-06-24       Impact factor: 8.694

9.  Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study.

Authors:  Jorge R Kizer; David Benkeser; Alice M Arnold; Kenneth J Mukamal; Joachim H Ix; Susan J Zieman; David S Siscovick; Russell P Tracy; Christos S Mantzoros; Christopher R Defilippi; Anne B Newman; Luc Djousse
Journal:  Circulation       Date:  2012-11-16       Impact factor: 29.690

10.  Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults.

Authors:  Christopher R deFilippi; James A de Lemos; Andrew T Tkaczuk; Robert H Christenson; Mercedes R Carnethon; David S Siscovick; John S Gottdiener; Stephen L Seliger
Journal:  J Am Coll Cardiol       Date:  2012-11-14       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.